论文部分内容阅读
[目的]评价奥沙利铂(oxaliplatin,L-OHP)联合氟尿嘧啶(5-Fu)、亚叶酸钙(CF)一线治疗晚期胃癌的疗效及毒副反应。[方法]58例经病理学证实的晚期胃癌患者行奥沙利铂+5-Fu+CF联合化疗。2个周期化疗后评价疗效。[结果]58例患者中,完全缓解3例(5.2%),部分缓解19例(32.8%),稳定26例(44.8%),进展10例(17.2%),有效率38.0%。中位无进展生存期(PFS)6.7个月,中位总生存期(OS)10.1个月,1年生存率20.7%(12/58),无治疗相关性死亡。Log-Rank检验分析显示PFS及OS的预后因素包括PS评分及化疗周期数。主要毒副反应有中性粒细胞减少(24.1%)、外周神经系统病变(48.0%)、恶心呕吐(39.7%)和口腔炎(31.3%)。[结论]奥沙利铂联合5-Fu一线治疗晚期胃癌疗效肯定,毒副反应轻微。
[Objective] To evaluate the efficacy and side effects of oxaliplatin combined with 5-Fu and leucovorin in the treatment of advanced gastric cancer. [Method] Fifty-eight patients with advanced gastric cancer confirmed by pathology underwent combined oxaliplatin + 5-Fu + CF chemotherapy. After 2 cycles of chemotherapy evaluation of efficacy. [Results] Among 58 patients, complete remission was achieved in 3 cases (5.2%), partial remission in 19 cases (32.8%), stabilization in 26 cases (44.8%), progression in 10 cases (17.2%) and effective rate of 38.0%. The median progression-free survival (PFS) was 6.7 months. The median overall survival (OS) was 10.1 months and the 1-year survival was 20.7% (12/58) with no treatment-related death. Log-rank test showed that prognostic factors of PFS and OS included PS score and the number of chemotherapy cycles. The main toxicities were neutropenia (24.1%), peripheral nervous system diseases (48.0%), nausea and vomiting (39.7%) and stomatitis (31.3%). [Conclusion] The efficacy of oxaliplatin combined with 5-Fu first-line treatment of advanced gastric cancer is affirmative, and the side effects are mild.